Chimerix Sees Options For Brincidofovir Despite Disappointing CMV Data
This article was originally published in The Pink Sheet Daily
The company is analyzing data from subsets of patients in the Phase III SUPPRESS trial evaluating brincidofovir for the prevention of cytomegalovirus in patients undergoing hematopoietic cell transplantation.
You may also be interested in...
The company is planning a direct-to-consumer education campaign to inform the public about the importance of vaccination.
The company showcased its pipeline in a two-day virtual meeting, trying to convince investors the long-term potential is undervalued.
Merck & Co. will pay Seattle Genetics $725m up front in cash under the two deals and make a $1bn equity investment in the company, providing financial flexibility to broadly fund the pipeline.